Evaluation Study for the Programme DiaNe for People With Diabetic Nephropathy (DiaNe)
Primary Purpose
Diabetic Nephropathy
Status
Completed
Phase
Phase 3
Locations
Germany
Study Type
Interventional
Intervention
DiaNe consultation and support program
Sponsored by
About this trial
This is an interventional supportive care trial for Diabetic Nephropathy focused on measuring diabetes mellitus, diabetic nephropathy, hypertension
Eligibility Criteria
Inclusion Criteria:
- diabetes mellitus
- proven diabetic nephropathy by histological/lab findings and/or discretion of nephrologist
- ability to understand the German language
Exclusion Criteria:
- end stage renal disease and/or dialysis
- unable or unwilling to follow the protocol
- pregnant women
- discretion of nephrologist
Sites / Locations
- Diabetes- und Nierenzentrum Dormagen
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
No Intervention
Arm Label
with DiaNe program
without DiaNe program
Arm Description
study subjects which participated in the DiaNe consultation and support program
study subjects which received standard care by diabetologist and/or nephrologist
Outcomes
Primary Outcome Measures
deterioration of kidney function in diabetic nephropathy
Secondary Outcome Measures
HbA1c
Full Information
NCT ID
NCT00782847
First Posted
October 30, 2008
Last Updated
October 30, 2008
Sponsor
DiaNe HCM GmbH
Collaborators
Roche Pharma Deutschland GmbH, Grenzach-Wyhlen, Germany, Institute for Medical Outcom Research GmbH, Loerrach, Germany
1. Study Identification
Unique Protocol Identification Number
NCT00782847
Brief Title
Evaluation Study for the Programme DiaNe for People With Diabetic Nephropathy
Acronym
DiaNe
Official Title
A Prospective Controlled Randomized Multicenter Trial to Evaluate the Effect of a Structurized Multifactorial Behavior Modifying Consultation and Support Programme DiaNe for People With Diabetic Nephropathy
Study Type
Interventional
2. Study Status
Record Verification Date
October 2008
Overall Recruitment Status
Completed
Study Start Date
July 2004 (undefined)
Primary Completion Date
January 2007 (Actual)
Study Completion Date
January 2007 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
DiaNe HCM GmbH
Collaborators
Roche Pharma Deutschland GmbH, Grenzach-Wyhlen, Germany, Institute for Medical Outcom Research GmbH, Loerrach, Germany
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study is designated to evaluate the effect of a patients' educational program called DiaNe® for consultation and support people with diabetic kidney disease in an early stage. The aim of the study is to examine if the program is suitable to stop deterioration of kidney function and to maintain or improve glycemic control. The consultation and support program DiaNe® substantially contributes to a better understanding of the affected clients for this complex clinical picture, allows them for specific interventions and creates the rationale for an active therapeutic relationship.
Detailed Description
According to statistics diabetes mellitus is considered to be the leading cause for end stage renal disease in Germany, approximately 35% of the patients starting on dialysis are affected by diabetes-induced nephropathy. This can be seen in countries all over the world. This situation has been known for years. To date, neither structured intervention methods nor educational programs have been designed for and targeting those affected, which would consequently allow for structured, multifactorial intervention at an early stage of diabetic nephropathy. Multifactorial interventions, as published in the Steno-2 trial, appear to be highly effective with regard to long-term complications of diabetes. In order to realize this approach for the affected as well as the medical staff caring for patients with diabetes-induced nephropathy we developed DiaNe®, a consultation and support program, which is designed to give detailed information to the affected in order to induce behavioral changes. We were able to show a clinically significant reduction of microalbuminuria within a first monocenter evaluation trial. We wanted to verify this effect by means of a prospective multicenter randomized cohort trial according to GCP-ICH guidelines.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetic Nephropathy
Keywords
diabetes mellitus, diabetic nephropathy, hypertension
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
125 (Actual)
8. Arms, Groups, and Interventions
Arm Title
with DiaNe program
Arm Type
Active Comparator
Arm Description
study subjects which participated in the DiaNe consultation and support program
Arm Title
without DiaNe program
Arm Type
No Intervention
Arm Description
study subjects which received standard care by diabetologist and/or nephrologist
Intervention Type
Behavioral
Intervention Name(s)
DiaNe consultation and support program
Other Intervention Name(s)
DiaNe program, DiaNe(R)
Intervention Description
the DiaNe consultation and support program for clients with diabetic nephropathy consists of 4 sessions at 90-120 minutes conducted every week in a period of 4 weeks
Primary Outcome Measure Information:
Title
deterioration of kidney function in diabetic nephropathy
Time Frame
13 months
Secondary Outcome Measure Information:
Title
HbA1c
Time Frame
13 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
diabetes mellitus
proven diabetic nephropathy by histological/lab findings and/or discretion of nephrologist
ability to understand the German language
Exclusion Criteria:
end stage renal disease and/or dialysis
unable or unwilling to follow the protocol
pregnant women
discretion of nephrologist
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ludwig F Merker, MD
Organizational Affiliation
Diabetes- und Nierenzentrum Dormagen
Official's Role
Principal Investigator
Facility Information:
Facility Name
Diabetes- und Nierenzentrum Dormagen
City
Dormagen
State/Province
NRW
ZIP/Postal Code
D-41539
Country
Germany
12. IPD Sharing Statement
Learn more about this trial
Evaluation Study for the Programme DiaNe for People With Diabetic Nephropathy
We'll reach out to this number within 24 hrs